Overview of patient characteristics in NTM lung surgery studies performed to date
| First author [ref.] | Study year(s), location | Patients n | Median (range) age years | Females % | NTM species | Lung involvement and/or comorbidities |
| Studies without clarithromycin | ||||||
| Elkadi [23] | 1962–1973 Missouri, USA | 48 | 48 (20–72) | 33% | M. kansasii 54% M. intracellulare 42% Rapid grower 2% | Lung cavities 77% |
| Pomerantz [36] | 1983–1990 Colorado, USA | 38 | 50 (33–39) | 68% | MAC 87% M. kansaii 3% M. chelonae 3% M. xenopi 3% | Previous lobectomy 18% Previous TB 8% Bronchopleural fistula 8% Chest radiation 8% |
| Ono [35] | 1991–1996 Wakayama, Japan | 8 | 50 (36–72) | 50% | MAC 100% | Cigarette smoker 25% Bronchiectasis, 25% Previous TB 25% Sjögren's syndrome 13% |
| Nelson [38] | 1989–1997 Texas, USA | 28 | Mean±sd 50±11 | 25% | MAC 100% | Almost all were smokers 67% >20% below weight standard No immunocompromised |
| Shiraishi [34] | 1979–1996 Tokyo, Japan | 33 | 50 (30–69) | 48% | MAC 100% | Cigarette smoker 97% Bronchiectasis 21% Cavity 64%; nodule 3% Previous TB 9% Pneumonia 9% |
| Studies incorporating clarithromycin | ||||||
| Shiraishi [28] | 1993–2001 Kyoto, Japan | 21 | 56 (27–67) | 48% | MAC 100% | Bronchiectasis 10% Cavity 76%; nodule 10% Destroyed lung 5% No immunocompromised |
| Shiraishi [29] | 1983–2002 Tokyo, Japan | 11 | 57 (43–69) | 73% | MAC 91% M. abscessus 9% | Multiple cavities 55% Destroyed lung 46% Bilateral disease 36% No immunocompromised |
| Watanabe [39] | 1990–2005 Tokyo, Japan | 22 | 54 (30–77) | 68% | MAC 100% | Bronchiectasis predominant 64% Cavitary predominant 36% No immunocompromised |
| Mitchell [43] | 1983–2006 Colorado, USA | 236 | 54 (23–77) | 83% | MAC 80% M. abscessus 14% | Focal bronchiectasis 55% Cavitary lung disease 29% Mixed pattern 9% Prior thoracic surgery 20% |
| Koh [40] | 2002–2007 Seoul, Korea | 23 | 45 (24–66) | 70% | MAC 43% M. abscessus 52% M. xenopi 4% | Cavities 70% Bronchiectasis 30% No immunocompromised |
| van Ingen [19] | 2000–2009 Holland | 8 | 52 (41–59) | 25% | MAC 88% M. xenopi 12% | Cavitary 62% Mixed pattern 25% Bronchiectasis 13% No immunocompromised |
| Yu [30] | 2004–2009 Colorado, USA | 128 | 59 (34–81) | 96% | MAC 88% M. abscessus or chelonae 10% | Bronchiectasis 95% Cigarette smoker 16% Cavitary disease 3% Mixed pattern 2% Prior thoracic procedure 10% |
| Jarand [41]# | 2001–2008 Alberta, Canada | 24 | Mean±sd 57.7±11.1 | 83% | M. abscessus 100% | Localised bronchiectasis 86% Coexisting/previous MAC 54.2% Cavitary disease 37% Previous smokers 23% Previous TB 8.3% |
| Shiraishi [31] | 2007–2011 Tokyo, Japan | 60 | 50 (20–72) | 68% | MAC 92% M. abscessus 5% M. gordonae 2% M. xenopi 2% | Bronchiectasis 48% Cavities 42% Cigarette smoker 18% Mixed pattern 7% Diabetes mellitus 6.7% |
| Asakura [37] | 1994–2015 Yokohama, Japan | 125 | 60 (IQR 49–66) | 53% | MAC 80% M. intracellulare 8% M. abscessus 5% M. kansasii 3% Others 5% | Cavities 70%; nodules 98% Bronchiectasis 89% Cigarette smoker 29% Old TB 26%, COPD 10% Diabetes mellitus 10% |
M. kansasii: Mycobacterium kansasii; M. intracellulare: Mycobacterium intracellulare; M. chelonae: Mycobacterium chelonae; M. xenopi: Mycobacterium xenopi; M. abscessus: Mycobacterium abscessus; M. gordonae: Mycobacterium gordonae; IQR: interquartile range; COPD: chronic obstructive pulmonary disease. #: compared combined antibiotic and surgical treatment with antibiotic treatment alone.